Merck, Ferring Pharmaceuticals and the World Health Organization Working Together to Prevent Excessive Bleeding in Women after

  Merck, Ferring Pharmaceuticals and the World Health Organization Working
  Together to Prevent Excessive Bleeding in Women after Childbirth

           Post-partum Hemorrhage Is Leading Cause of Mothers Dying

Business Wire

WHITEHOUSE STATION, N.J. -- April 4, 2014

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Ferring Pharmaceuticals today announced their collaboration with the World
Health Organization (WHO) to advance a new, proprietary formulation of
carbetocin, used to prevent excessive bleeding (post-partum hemorrhage) in
women after childbirth, that is designed to be stable at room temperature,
even in hot and tropical climates (ICH climatic zone IV). Currently, oxytocin,
the standard medicine administered for the prevention of excessive bleeding,
is temperature-sensitive and requires sustained cold distribution and storage
in hot climates. The WHO will conduct a multi-country clinical study to
evaluate the effectiveness of room-temperature-stable carbetocin, as compared
to oxytocin. The development of a medicine that can be stored at room
temperature has the potential to significantly improve management of bleeding
following childbirth in the many areas of the world where cold storage is
difficult to achieve and maintain, and thereby help reduce maternal deaths in
those areas.

Starting this year, the study will take place in 12 countries around the world
and enroll approximately 29,000 women. If the results of the study are
positive, the organizations will work together with the aim of making the
medicine available in developing countries that have a high burden of maternal
mortality at an affordable and sustainable public-sector price.

“Mothers hold the future in their hands. That’s why Merck has taken on our
10-year, $500 million fight against maternal mortality,” said Kenneth C.
Frazier, chairman and chief executive officer, Merck. “Working with our
partners, we can help make a better solution a reality. It would be a real
breakthrough to help prevent the number-one cause of women dying in childbirth
in the most vulnerable parts of the globe.” Through its Merck for Mothers
initiative, Merck is applying its scientific and business expertise – as well
as its financial resources – to reduce maternal mortality around the world.

“Few tragedies compare to the death of a mother during childbirth. Obstetric
treatments that benefit mother and baby are a key focus of our efforts at
Ferring. Ferring originally developed carbetocin and received the indication
for the prevention of post-partum hemorrhage more than a decade ago. Ferring
is delighted to join with the WHO and Merck in this project that aims to make
the benefits of carbetocin available in areas of the world where cold storage
is not readily available,” said Michel L. Pettigrew, President of the
Executive Board and COO, Ferring Group.

About Carbetocin

Carbetocin is not available in the United States. The WHO study of
room-temperature-stable carbetocin will take place in Argentina, Brazil,
Egypt, India, Kenya, Nigeria, Pakistan, Singapore, South Africa, Thailand,
Uganda and the United Kingdom.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical
group, headquartered in Switzerland, and active in global markets. The company
identifies, develops and markets innovative products in the areas of
reproductive health, urology, gastroenterology and endocrinology. Ferring’s
obstetric portfolio (available in various countries outside the USA) includes
carbetocin, a medicine which prevents post-partum hemorrhage, atosiban, a
medicine which delays imminent preterm birth and dinoprostone and misoprostol
to be used in connection with labour induction. Ferring has its own operating
subsidiaries in 55 countries and markets its products in more than 100
countries. To learn more about Ferring or its products please visit
www.ferring.com.

About Merck for Mothers

Every two minutes, a woman dies from complications related to pregnancy and
childbirth. If nothing is done an estimated three million women may die from
complications of pregnancy and childbirth in the next decade. Most of these
deaths are preventable. While the burden falls most heavily on the developing
world, certain communities in the United States and other developed nations
are suffering significant and worsening rates of maternal death.

Merck for Mothers is a 10-year, $500 million initiative focused on creating a
world where no woman has to die from complications of pregnancy and
childbirth. Drawing on the company's history of discovering innovative,
life-saving medicines and vaccines, Merck for Mothers is applying Merck's
scientific and business expertise – as well as its financial resources and
experience in taking on tough global healthcare challenges – to reduce
maternal mortality around the world. For more information, visit
www.merckformothers.com and connect with us on Facebook.

About Merck

Today's Merck is a global healthcare leader working to help the world be well.
Merck is known as MSD outside the United States and Canada. Through our
prescription medicines, vaccines, biologic therapies, and consumer care and
animal health products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching policies,
programs and partnerships. For more information, visit www.merck.com and
connect with us on Twitter, Facebook and YouTube.

Merck Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially from those set
forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest rate
and currency exchange rate fluctuations; the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory
approval; Merck’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of Merck’s
patents and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those
described in the forward-looking statements can be found in Merck’s 2013
Annual Report on Form 10-K and the company’s other filings with the Securities
and Exchange Commission (SEC) available at the SEC’s Internet site
(www.sec.gov).

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20140404005156/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50838216&lang=en

Contact:

Merck
Media:
Jennifer Allen Woodruff, 267-305- 3550
or
Lainie Keller, 908-423-4187
or
Investor:
Carol Ferguson, 908-423-4465
or
Ferring Media:
Helen Gallagher, +41 58 301 0051
or
Patrick Gorman, +41 58 301 0053
 
Press spacebar to pause and continue. Press esc to stop.